

CA-ADAP Review: N-Acetylcysteine for Cannabis Use Disorder

July 2024 CARRIE HOLDEN, PHARM.D



Substance Use Disorder (SUD)



SUD is complex, where there is uncontrolled use despite harmful consequences

- People with SUD have an intense focus (addiction) on using a certain substance(s) to the point where the ability to function in daily life is impacted
- ▶ Repeated substance use can cause brain-function changes

Cannabis Use Disorder (CUD)




The inability to stop using cannabis even when it causes harm

- Risk of cannabis use disorder (CUD) is estimated to affect
 ~10% of users
- No approved pharmacological treatment
- Treatment often complicated by comorbid conditions
- N-Acetylcysteine (NAC) has shown promising results

NAC and Glutamate Dysregulation





- By the time most people seek treatment, years of chronic substance use have likely led to significant brain-related adaptations
- With repeated substance use, a stronger urge to use the drug develops, driven more by compulsion
- Numerous neural adaptations underlie the transition from "liking" to compulsive use


Clinical Trials with NAC for the Treatment of CUD



Study	Sample	Dosing	Outcomes
Gray et al (2010)	N = 24 adolescents/emerging adults (age 18 to 21) with cannabis dependence (75% male, 92% white)	1,200 mg twice daily (2,400 mg/d) for 4 weeks (open-label)	•Reduction in self-reported number of cannabis use days and number of "hits" per day •Reduction in self-reported craving •Non-significant reduction in semi-quantitative creatinine- normalized cannabinoid levels
Gray et al (2012); Roten et al (2013)	N = 116 adolescents (ages 15 to 21) with cannabis dependence (72% male, 84% white)	1,200 mg twice daily (2,400 mg/d) vs placebo for 8 weeks (double-blind) added to contingency management	Double the odds of abstinence in NAC group relative to placebo (as confirmed via urine cannabinoid test) at end of treatment No group differences in self- reported number of cannabis use days or craving
Gray et al (2017)	N = 302 adults with cannabis use disorder (77% male, 55% white, 29% black/African American)	1,200 mg twice daily (2,400 mg/d) vs placebo for 12 weeks (double-blind) added to contingency management	•No group differences in odds of abstinence •No group differences in self- reported number of cannabis use days •Numerical, non-significant trend for double odds of abstinence among younger age group receiving NAC vs placebo (age 18 to 21)

Clinical Implications of NAC for CUD





Combined with contingency management, NAC may be efficacious for adolescents with cannabis use disorder, with treatment gains evident by the 4th week of treatment

Other Uses for N-Acetylcysteine



For the treatment of acetaminophen overdose to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen



Can be given as IV infusion, oral solution, or oral nebulizer solution

For adjunctive treatment of chronic obstructive pulmonary disease (COPD) as well as tuberculosis, bronchiectasis, and primary amyloidosis of the lung



Given as nebulization (via face mask, mouth piece, or tracheostomy), or by intratracheal instillation

For mucolysis of viscous or inspissated mucous secretions in patients with pulmonary conditions and for use during tracheostomy care, anesthesia, and diagnostic bronchograms



Given as nebulization (via face mask, mouth piece, or tracheostomy) or intratracheal instillation

OFF LABEL USE:

For nephrotoxicity prophylaxis against radiographic-contrastinduced reactions



Given orally or IV

References



Clinical Pharmacology (no date) Clinical Pharmacology. Available at: https://www.clinicalkey.com/pharmacology (Accessed: 11 July 2024).

Sharma, R. et al. (2022) N-acetyl cysteine in the treatment of Cannabis Use Disorder: A systematic review of Clinical Trials, Addictive Behaviors. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0306460322000491 (Accessed: 11 July 2024).

Singh, Dr.H. (2022) CAN NAC help with cannabis use disorder?, Psychiatry Education Forum. Available at: https://psychiatryeducationforum.com/nac-cannabis/ (Accessed: 11 July 2024).

Tomko, R.L. et al. (2018) n-acetylcysteine: A potential treatment for substance use disorders, Current psychiatry. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993450/ (Accessed: 11 July 2024).

What is a substance use disorder? (2024) Psychiatry.org - What Is a Substance Use Disorder? Available at: https://www.psychiatry.org/patients-families/addiction-substance-use-disorders/what-is-a-substance-use-disorder (Accessed: 11 July 2024).

By receipt of this material, each recipient agrees that the information contained herein will be kept confidential and will not be photocopied, reproduced or distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics and Magellan Rx.

The information contained in this presentation is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment. The information here should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.